This Pompe disease NSC model was used to evaluate therapeutic responses to δ-tocopherol, hydroxypropyl-beta-cyclodextrin (HPβCD), and recombinant human GAA (rhGAA). This evidence concerns the gene GAA and glycogen storage disease II.